---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-25-004450"
form_type: "8-K"
ticker: "NTHI"
cik: "0001979414"
company_name: "NEONC TECHNOLOGIES HOLDINGS, INC."
filed_at: "2025-06-12T23:59:59+00:00"
generated_at: "2026-05-19T11:31:02.382388+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NeOnc Technologies appoints Dr. Josh Neman as Chief Clinical Officer

## Summary
- Dr. Josh Neman, PhD, appointed CCO; formerly Associate Professor at USC Keck School and Scientific Director of USC Brain Tumor Center.
- He will lead clinical strategy for four trials, including NEO100 approaching Phase 2a completion with full enrollment ahead of schedule.
- Neman's research on tumor-neuron interactions and GABAergic signaling supports FDA approval path and AI/quantum computing integration.
- Appointment aims to accelerate precision therapies for CNS cancers; NeOnc holds 176 patents worldwide.

## SEC filing metadata
- accession: 0001829126-25-004450
- form_type: 8-K
- ticker: NTHI
- cik: 0001979414
- company_name: NEONC TECHNOLOGIES HOLDINGS, INC.
- filed_at: 2025-06-12T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1979414/000182912625004450/0001829126-25-004450-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1979414/000182912625004450/neonctechnologies_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-25-004450
- JSON: https://secwatch.observer/filing/0001829126-25-004450.json
- Plain text: https://secwatch.observer/filing/0001829126-25-004450.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.